Combined modality therapy of esophageal carcinoma

Kelsen, David P.; Ahuja, Rajender K.; Hopfan, Seymour; Bains, Manjit S.; Kosloff, Cynthia; Martini, Nael; McCormack, Patricia; Golbey, Robert B.

doi:10.1002/1097-0142(19810701)48:1<31::aid-cncr2820480108>3.0.co;2-4

Cited by 49 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our initial study with cisplatin and bleomycin in combined modality therapy suggested that the resection rate of patients receiving preoperative chemotherapy was superior to that seen in a historical control group receiving preoperative radiation therapy (76% versus 5470, P < 0.04), with similar operative mortality ( 1 1% and 12% respectively). 16 Using the three drug combination of DVB, the 82% resection rate seen to date supports the observation that preoperative chemotherapy is at least as good as preoperative irradiation, and, as noted above, may offer superior resection rates. Systemic chemotherapy has the theoretical advantage, in comparison to radiation, of allowing treatment of both the primary tumor and of metastases outside the local area.…”

Section: Discussionsupporting

confidence: 52%

Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin

Kelsen¹,

Bains²,

Hilaris³

et al. 1982

Cancer

Self Cite

View full text Add to dashboard Cite

Sixty-one patients with epidermoid carcinoma of the esophagus have been treated with a three drug combination of cisplatin, vindesine, and bleomycin. Of 53 patients currently evaluable for response, 29 (55%) have had partial remissions: 7/16 with metastatic, and 22/37 with local-regional disease. The median duration of response in metastatic patients is eight months. Of 28 patients treated preoperatively, 23 (82%) had resectable disease. The major toxicities seen were nephrotoxicity and myelosuppression. Cisplatin, vindesine and bleomycin is an effective combination in the treatment of esophageal carcinoma. Effects on long-term survival cannot yet be evaluated.

show abstract

Section: Discussionsupporting

confidence: 52%

Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin

Kelsen¹,

Bains²,

Hilaris³

et al. 1982

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Gisselbrecht et al 9) have reported that the objective response rate in 21 patients receiving combination chemotherapy with 5-FU, adriamycin, and cisplatin was 33%, but the median length of survival was only 8 months. Various combinations of treatment modalities, such as surgery with pre- or postoperative radiotherapy, 5 , 10 , 11) preoperative chemotherapy followed by surgery, 12) and combinations of radiotherapy and chemotherapy, 8 , 12) have been tried to improve the response rate and longterm survival, demonstrating that combined modality treatment has not been always advantageous compared with single modality treatment. 10) Some reports have shown that the combination of chemotherapy with radiotherapy was much more efficient than single modality with chemotherapy or radiotherapy for inoperable esophageal cancer.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Study on Radiotherapy and Radiochemotherapy in Esophageal Cancer

Kim

Hong

Lee

et al. 1988

Korean J Intern Med

View full text Add to dashboard Cite

One hundred nineteen patients with inoperable esophageal cancer who had been treated with radiotherapy and/or chemotherapy from Jan. 1982 to Dec. 1986 at the Korea Cancer Center Hospital were retrospectively analyzed. Of 119 patients, 111 were male, and eight were female. Ten (8%) had a lesion in the cervical esophagus; 71 (60%), in the upper and midthoracic esophagus; and 38 (32%), in the lower esophagus. One hundred ten (92%) patients had squamous cell carcinoma, and nine (8%) had adenocarcinoma. In 40 patients receiving radiotherapy alone, the response rate was 50% (complete response, 10%; partial response, 40%) with a median survival of 9 months. The 1-, 2-, and 3-year survival rates were 35%, 10%, and 5%, respectively. In 36 patients receiving radiochemotherapy, the response rate was 61% (complete response. 20%; partial response, 41%) with a median survival of 15 months. The 1-, 2-, and 3-year survival rates were 45%, 31%, and 12%, respectively. Six patients who had received chemotherapy alone had no objective response and died within one year. None of the 37 patients who had not received a specific treatment for underlying cancer survived two years. T1 stage, a lesion in the cervical esophagus, and good performance status (0–2) were considered to be favorable prognostic factors. There was no significant difference in the response rate and the actuarial survival between the radiotherapy and radiochemotherapy groups. These results suggest that both radiotherapy and radiochemotherapy are effective treatment modalities for inoperable esophageal cancer.

show abstract

“…We were prompted to utilize only DB chemotherapy preoperatively because we observed it to have activity in patients with advanced disease, and because our experience with preoperative radiation therapy at this institution showed a 5-year survival rate of 5%. 8 We reasoned that preoperative treatment with chemotherapy, unlike preoperative radiation therapy, had the potential advantage of destroying tumor at the primary site as well as in occult metastatic sites.…”

Section: Discussionmentioning

confidence: 99%

Cisplatin and bleomycin in the treatment of esophageal carcinoma: A final report

Coonley

Bains

Hilaris

et al. 1984

Cancer

Self Cite

View full text Add to dashboard Cite

During the period from September, 1976 to June, 1979, 70 patients with locoregional or extensive epidermoid carcinoma of the esophagus were treated with the two‐drug combination of cisplatin and bleomycin (DB). For the 43 patients with locoregional disease (LRD), DB was used prior to surgery and/or radiation therapy; it was the primary treatment for 27 patients with extensive disease (ED). The major objective response rates [complete remission (CR) and partial remission (PR)] to DB for the LRD and ED groups were 14% and 17%, respectively, for an overall response rate of 15%. For the LRD group, the minimum follow‐up was 42 months; four patients (10%) remain alive and free of disease. The median survival of 34 patients treated with DB preoperatively was 10 months, which did not differ significantly from that of a historic control group receiving preoperative radiation therapy. The median duration of response for ED patients was 6 months, and the median survival for the entire ED group was 4 months. DB alone had only modest activity in epidermoid carcinoma of the esophagus.

show abstract

Combined modality therapy of esophageal carcinoma

Cited by 49 publications

References 14 publications

Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin

Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin

A Retrospective Study on Radiotherapy and Radiochemotherapy in Esophageal Cancer

Cisplatin and bleomycin in the treatment of esophageal carcinoma: A final report

Contact Info

Product

Resources

About